https://doi.org/10.4081/monaldi.2024.3149
Optimal treatment strategies for coronary heart disease in cancer patients: a complex clinical case
Published: September 12, 2024
Abstract Views: 176
PDF_EARLY VIEW: 88
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Coronary heart disease (CHD) remains a leading cause of mortality among cancer patients, primarily due to shared risk factors and the impacts of chemotherapeutic drugs, immune checkpoint inhibitors, and radiotherapy. Determining the optimal treatment strategy remains a challenging issue for patients with concurrent CHD and malignant neoplasms. In high-risk patients, managing CHD frequently takes precedence over addressing the oncologic disease. Myocardial revascularization, coupled with optimal medical therapy for CHD, can significantly enhance patient survival by reducing the risks of myocardial infarction and sudden cardiac death. However, selecting a surgical treatment strategy requires careful consideration of the indications, the complexity of coronary lesions, the risk of bleeding and thrombosis, and the overall prognosis of the malignancy. This clinical case demonstrates the importance of risk-benefit assessment, multidisciplinary discussion of cure strategy, and application of novel technologies to provide the most personalized and effective treatment.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63.
DOI: https://doi.org/10.3322/caac.21834
Davydov MI, Akchurin RS, Gerasimov SS, et al. Simultaneous surgery of competing cardio-vascular and malignant diseases of lungs and mediastinum. Khirurgiia 2010;8:4-10. [Article in Russian].
Rupprecht S, Finn S, Hoyer D, et al. Association between systemic inflammation, carotid arteriosclerosis, and autonomic dysfunction. Transl Stroke Res 2020;11:50-9.
DOI: https://doi.org/10.1007/s12975-019-00706-x
Buziashvili YI, Asymbekova EU, Matskeplishvili ST, et al. Dynamics of echocardiographic parameters during neoadjuvant chemotherapy in patients with breast cancer. Creative Cardiology 2022;16:520-32.
Mamas MA, Brown SA, Sun LY. Coronary artery disease in patients with cancer: it's always the small pieces that make the bigger picture. Mayo Clin Proc 2020;95:1819-21.
DOI: https://doi.org/10.1016/j.mayocp.2020.07.006
Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation 2019;139:e997-1012.
DOI: https://doi.org/10.1161/CIR.0000000000000679
Laenens D, Yu Y, Santens B, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol 2022;40:3430-8.
DOI: https://doi.org/10.1200/JCO.21.01808
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361. Erratum in: Eur Heart J 2023;44:1621.
DOI: https://doi.org/10.1093/eurheartj/ehad196
Sarkar B. An incorrect impression of dose versus the ischemic cardiac toxicity risk profile for breast and chest wall radiation therapy. Int J Radiat Oncol Biol Phys 2020;106:451-2.
DOI: https://doi.org/10.1016/j.ijrobp.2019.11.006
Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41.
DOI: https://doi.org/10.1016/j.jacc.2007.06.037
Golukhova EZ, Slivneva IV, Kozlova OS, et al. Treatment strategies for chronic coronary heart disease with left ventricular systolic dysfunction or preserved ejection fraction-a systematic review and meta-analysis. Pathophysiology 2023;30:640-58.
DOI: https://doi.org/10.3390/pathophysiology30040046
Iannaccone M, D'Ascenzo F, Vadalà P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018;7:631-8.
DOI: https://doi.org/10.1177/2048872617706501
Kwok CS, Wong CW, Kontopantelis E, et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur. Heart J 2021;42:1019-34.
DOI: https://doi.org/10.1093/eurheartj/ehaa1032
Guo W, Fan X, Lewis BR, et al. Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention. JACC Cardiovasc Interv 2021;14:1094-105.
DOI: https://doi.org/10.1016/j.jcin.2021.03.049
Ueki Y, Vögeli B, Karagiannis A, et al. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol 2019;1:145-55.
DOI: https://doi.org/10.1016/j.jaccao.2019.11.001
Thomason N, Monlezun DJ, Javaid A, et al. Percutaneous coronary intervention in patients with gynecological cancer: machine learning-augmented propensity score mortality and cost analysis for 383,760 patients. Front Cardiovasc Med 2022;8:793877.
DOI: https://doi.org/10.3389/fcvm.2021.793877
Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 2018;7:265-73.
DOI: https://doi.org/10.21037/apm.2017.11.01
Han XJ, Li JQ, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med 2020;5:221-33.
DOI: https://doi.org/10.1016/j.cdtm.2019.12.007
Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2021;42:308-19.
DOI: https://doi.org/10.1093/eurheartj/ehaa739
Ahmed T, Pacha HM, Addoumieh A, et al. Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents. Front Cardiovasc Med 2022;9:901431.
DOI: https://doi.org/10.3389/fcvm.2022.901431
How to Cite
Golukhova, Elena Zelikovna, Inessa Viktorovna Slivneva, Andrey Lvovich Pylev, Olga Sergeevna Kozlova, Karen Valerievich Petrosyan, Denis Sergeevich Romanov, and Alexander Yurievich Volkov. 2024. “Optimal Treatment Strategies for Coronary Heart Disease in Cancer Patients: A Complex Clinical Case”. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2024.3149.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Commento bibliografico di Francesco Giallauria e Carlo Vigorito, Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes , Monaldi Archives for Chest Disease: Vol. 74 No. 1 (2010): Cardiac series
- G. Domenighetti, A. Moccia, R. Gayer, Observational case-control study of non-invasive ventilation in patients with ARDS , Monaldi Archives for Chest Disease: Vol. 69 No. 1 (2008): Pulmonary series
- K. Katsoulis, T. Kontakiotis, S. Gerou, M. Kougioulis, H. Lithoxopoulou, D. Papakosta, Alterations of Erythrocyte Superoxide Dismutase activity in patients suffering from asthma attacks , Monaldi Archives for Chest Disease: Vol. 73 No. 3 (2010): Pulmonary series
- X. Dhalluin, A. Scherpereel, Treatment of malignant pleural mesothelioma: current status and future directions , Monaldi Archives for Chest Disease: Vol. 73 No. 2 (2010): Pulmonary series
- Giovanni Esposito, Luigi Di Serafino, Giuseppe Gargiulo, Anna Sannino, Gabriele Giacomo Schiattarella, Anna Franzone, Cinzia Perrino, Massimo Chiariello, Rotational atherectomy for the treatment of isolated femoral artery traumatic lesion: a case report , Monaldi Archives for Chest Disease: Vol. 72 No. 3 (2009): Cardiac series
- D. Samolski, A. Antón, M. Mayos, M. Subirana, R. Güell, Primary alveolar hypoventilation and XXXXY chromosopathy , Monaldi Archives for Chest Disease: Vol. 65 No. 3 (2006): Pulmonary series
- R.W. Dal Negro, A. Testa, R. Aquilani, S. Tognella, E. Pasini, A. Barbieri, F. Boschi, Essential amino acid supplementation in patients with severe COPD: a step towards home rehabilitation , Monaldi Archives for Chest Disease: Vol. 77 No. 2 (2012): Pulmonary series
- M.J. Newport, S. Nejentsev, Genetics of susceptibility to tuberculosis in humans , Monaldi Archives for Chest Disease: Vol. 61 No. 2 (2004): Pulmonary series
- P.D.O. Davies, Risk factors for tuberculosis , Monaldi Archives for Chest Disease: Vol. 63 No. 1 (2005): Pulmonary series
- S. Katsenos, K. Kostikas, S. Lachanis, D. Sabaziotis, K. Psathakis, S. Loukides, Simultaneous pulmonary and intrathoracic lymph nodal granulomatosis of unknown significance (GLUS) , Monaldi Archives for Chest Disease: Vol. 61 No. 2 (2004): Pulmonary series
<< < 64 65 66 67 68 69 70 71 72 73 > >>
You may also start an advanced similarity search for this article.
